• SEQSTER Selected By MSAA, Owkin Expands Collaboration With Sanofi, Thermo Fisher Scientific Launches New Clinical Registry, More

    Clinical Research News | SEQSTER has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records, and cutting-edge longitudinal health record; Owkin adds immunology to Sanofi collaboration; Thermo Fisher Scientific launches a new CorEvitas syndicated clinical registry in generalized pustular psoriasis; and more.

    Mar 27, 2024

  • Follow the Money: Cystic Fibrosis Treatment, Advancing CAR-T Candidate, Modular T Cell Engagers, More

    Clinical Research News | Sionna Therapeutics plan to develop a first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein by stabilizing the first nucleotide-binding domain (NBD1); Capstan Therapeutics is advancing CPTX2309, the company’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp Therapeutics is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; and more.

    Mar 26, 2024

  • Electronic White Blood Cell Tracker Developed For Near-Patient Testing

    Clinical Research News | A revolution is underway in the diagnostics world that is reminiscent of what transpired in the computing field before the advent of PCs and smartphones. The unimagined possibilities of today will come from democratizing technology so that instead of sending patients to the lab, the lab will get sent to patients—and, ultimately, be available to them in the form of at-home testing kits.

    Mar 21, 2024

  • Latest Oral Insulin Drug Making Its Way To Clinical Trials

    Clinical Research News | More than a century has passed since the discovery of insulin, the world's first life-saving treatment for diabetes, and it is still being delivered via injection despite several brushes with success in developing an oral version of the drug. Hope is again on the horizon with the emergence of an oral nanotherapeutic formulation of insulin that comes with the possibility of reducing if not eliminating hypoglycemic events.

    Mar 20, 2024